BioSpace News Archive

Jesse Mendelsohn is a senior vice president at Model N, the leading revenue optimization and compliance provider for life sciences and high-tech manufacturers.

C-suite

Sophie Kornowski: From Medicine Taste-Tester to Data-Driven Dealmaker

What will Boston Pharmaceuticals CEO Sophie Kornowski do now that the company is selling off its pipeline and winding down operations? Whatever it is, data will take her there.

July 22, 2025

·

5 min read

·

Annalee Armstrong

Illustration of man waving big white flag, surreal abstract concept

Duchenne muscular dystrophy

Sarepta Concedes to FDA Request, Suspends US Shipments of Elevidys

After initially refusing to suspend Elevidys distribution after two deaths, Sarepta has now given in to the FDA’s request, noting the need to maintain a good working relationship with the regulator.

July 22, 2025

·

2 min read

·

Tristan Manalac

Big fish with a dollar badge wants to eat small fish

Mergers & acquisitions

Concentra Buys Beleaguered iTeos at Slight Discount

In May, biotech iTeos Therapeutics decided to close down after being abandoned by GSK over the disappointing mid-stage performance of its anti-TIGIT antibody belrestotug.

July 22, 2025

·

2 min read

·

Tristan Manalac

Searching for investments for a startup. Fundraising campaigns. Accumulation of funds. Search for investors and lending. New space race. A promising project

Funding

Avalyn Pharma Adds $100M Series D for Inhaled Pulmonary Fibrosis Drugs

The company is pushing inhaled versions of common oral drugs with the hope of avoiding severe side effects.

July 22, 2025

·

2 min read

·

Dan Samorodnitsky

Close-Up Of Syringe With Bottles Against Blue Background

Mergers & acquisitions

Sanofi Makes $1.6B Vaccine Bet With Vicebio Acquisition

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, follows the pharma’s potential $1.4 billion COVID vaccine licensing deal with Novavax last year, plus a number of other big-ticket commitments outside of the vaccine space.

July 22, 2025

·

2 min read

·

Tristan Manalac

A finger presses down on a businessman. Art collage.

Immuno-oncology

Replimmune Plummets Following FDA’s Surprise Rejection of Melanoma Treatment

BMO Capital Markets pointed to FDA leadership, and CBER Director Vinay Prasad in particular, as potential factors in the agency’s decision to issue a complete response letter for Replimmune’s viral treatment RP1 for advanced melanomas. Shares of the company tumbled 75% on Tuesday.

July 22, 2025

·

1 min read

·

Dan Samorodnitsky

Manufacturing

With Potential Tariffs Weeks Away, AstraZeneca Makes $50B U.S. Manufacturing Push

The money will focus on a manufacturing plant in Virginia that will make the company’s weight management and metabolic drugs like the hypertension drug baxdrostat and oral GLP-1 therapies.

July 22, 2025

·

2 min read

·

Tristan Manalac

IN PARTNERSHIP WITH ECLIPSEBIO

Why Countries Are Racing To Build mRNA Factories While America Hesitates on Next-Gen Vaccines

In this episode presented by Eclipsebio, BioSpace’s head of insights Lori Ellis continues the discussion on mRNA and srRNA with Andy Geall of Replicate Bioscience and Alliance for mRNA Medicines and Pad Chivukula of Arcturus Therapeutics.

July 22, 2025

·

1 min read

·

Lori Ellis

A pop art image of two hands polishing a vase

Editorial

Lack of Transparency Tarnishes Sarepta’s Sheen as Patient Deaths Trigger FDA Battle

Sarepta Therapeutics’ stock has dropped precipitously as questions swirl around the safety of its gene therapies. Meanwhile, the Duchenne patient community fears losing access to Elevidys while the regulator considers more drastic action.

July 22, 2025

·

6 min read

·

Jef Akst